Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1875 1
1879 1
1902 1
1921 1
1947 3
1949 2
1950 2
1951 3
1952 13
1953 6
1954 7
1955 5
1956 5
1957 8
1958 10
1959 5
1960 7
1961 7
1962 3
1963 15
1964 14
1965 12
1966 11
1967 13
1968 17
1969 10
1970 11
1971 12
1972 6
1973 15
1974 10
1975 7
1976 9
1977 11
1978 13
1979 23
1980 15
1981 19
1982 13
1983 17
1984 25
1985 28
1986 23
1987 48
1988 27
1989 28
1990 29
1991 30
1992 20
1993 23
1994 16
1995 26
1996 31
1997 25
1998 28
1999 41
2000 31
2001 29
2002 52
2003 71
2004 43
2005 47
2006 53
2007 53
2008 60
2009 65
2010 67
2011 76
2012 87
2013 116
2014 92
2015 120
2016 116
2017 153
2018 183
2019 207
2020 241
2021 267
2022 335
2023 364
2024 368
2025 424
2026 222

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,258 results

Results by year

Filters applied: . Clear all
Page 1
European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, Olszewska M, Ovcharenko YS, Piraccini BM, Prohic A, Rakowska A, Reygagne P, Richard MA, Soares RO, Starace M, Vañó-Galvan S, Waskiel-Burnat A. Rudnicka L, et al. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):687-694. doi: 10.1111/jdv.19768. Epub 2024 Jan 2. J Eur Acad Dermatol Venereol. 2024. PMID: 38169088 Review.
A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia areata. When using the AAS, moderate to severe alopecia areata should be considered a medical indication for systemic treatme …
A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia areata …
Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, Kiuru M. Barton VR, et al. J Am Acad Dermatol. 2022 Jun;86(6):1318-1334. doi: 10.1016/j.jaad.2021.04.077. Epub 2021 Apr 30. J Am Acad Dermatol. 2022. PMID: 33940103 Free PMC article.
BACKGROUND: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking. ...
BACKGROUND: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children …
Baricitinib for the Treatment of Alopecia Areata.
Freitas E, Guttman-Yassky E, Torres T. Freitas E, et al. Drugs. 2023 Jun;83(9):761-770. doi: 10.1007/s40265-023-01873-w. Epub 2023 May 17. Drugs. 2023. PMID: 37195491 Free PMC article. Review.
Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss that can affect any hair-bearing site. ...Its pathogenesis involves immune and genetic factors and several pro-inflammatory cytokines involved …
Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss tha …
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
Sterkens A, Lambert J, Bervoets A. Sterkens A, et al. Clin Exp Med. 2021 May;21(2):215-230. doi: 10.1007/s10238-020-00673-w. Epub 2021 Jan 1. Clin Exp Med. 2021. PMID: 33386567 Review.
Patients suffering from alopecia areata (AA) can lose hair in focal regions, the complete scalp, including eyelashes and eyebrows, or even the entire body. ...The prognosis is uncertain and is negatively influenced by the subtypes alopecia totalis and alop …
Patients suffering from alopecia areata (AA) can lose hair in focal regions, the complete scalp, including eyelashes and eyebr …
Janus kinase inhibitors for alopecia areata.
King BA, Craiglow BG. King BA, et al. J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049. J Am Acad Dermatol. 2023. PMID: 37591562 Review.
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly re …
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refra …
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D, Chen Y, Shen Y, Xie B, Song X. Wei D, et al. Front Immunol. 2023 Apr 17;14:1152513. doi: 10.3389/fimmu.2023.1152513. eCollection 2023. Front Immunol. 2023. PMID: 37138884 Free PMC article.
BACKGROUND: Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the widespread application of JAK inhibitors in immune-related diseases, attention is being given to their role in the treatment of AA. ...In terms of safety, …
BACKGROUND: Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the widespread application …
Alopecia Areata: Current Treatments and New Directions.
Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Dahabreh D, et al. Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22. Am J Clin Dermatol. 2023. PMID: 37606849 Review.
Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the hair follicle level. ...Given the recent US FDA approval of baricitinib and ritlecitinib, Janus kinase (JAK) inhibitors are a promising drug c …
Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the ha …
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Free article. Clinical Trial.
BACKGROUND: Alopecia areata is characterised by non-scarring loss of scalp, face, or body hair. We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, in patients with alopecia areata. ...INTE …
BACKGROUND: Alopecia areata is characterised by non-scarring loss of scalp, face, or body hair. We investigated the efficacy a …
Treatment of alopecia areata: An Australian expert consensus statement.
Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, Joseph S, Chitreddy V, Gunatheesan S, Sindhu K, Sharma P, Green J, Eisman S, Yip L, Jones L, Sinclair R. Cranwell WC, et al. Australas J Dermatol. 2019 May;60(2):163-170. doi: 10.1111/ajd.12941. Epub 2018 Nov 8. Australas J Dermatol. 2019. PMID: 30411329
Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. ...The optimal treatment algorithm has not yet been described. The purpose of this consensus statement is to outline a treatme …
Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebro …
Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA, Tosti A. Ramírez-Marín HA, et al. Expert Opin Emerg Drugs. 2022 Dec;27(4):379-387. doi: 10.1080/14728214.2022.2149735. Epub 2022 Nov 21. Expert Opin Emerg Drugs. 2022. PMID: 36408593 Review.
INTRODUCTION: Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. ...However, even new, effective treatments are not effective in all patients and recurrence …
INTRODUCTION: Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 a …
4,258 results